Goldman Sachs Group Inc Belite Bio, Inc Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Belite Bio, Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 6,326 shares of BLTE stock, worth $357,861. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,326Holding current value
$357,861% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BLTE
# of Institutions
22Shares Held
94KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.14 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$827,9580.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$760,9230.0% of portfolio
-
Xtx Topco LTD London, X07.06KShares$399,4970.04% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$379,0190.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.41B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...